BERLIN (Reuters) – Shares in Siemens Healthineers rose on Wednesday after the German well being group stated it anticipated its newly-acquired Varian enterprise to develop quicker than different divisions within the coming three years, boosting the group’s income.

Healthineers stated income at Varian, the U.S. most cancers remedy specialist it purchased earlier this yr in a $16.4 billion deal, ought to develop between 9% and 12% annually with working return on gross sales rising to effectively over 20% till 2025.

The corporate raised its synergy targets from the Varian takeover to greater than 350 million euros ($396 million) by 2025, from a earlier purpose of 300 million euros.

Shares in Healthineers had been up 4.8% at 0822 GMT, topping the German blue-chip index.

It expects annual comparable income progress of 6%-8% between 2023 and 2025 for the group, up from the 5%-7% forecast it anticipated for the fiscal yr 2022, excluding COVID-19 exams.

Earnings per share would rise 12%-15% annually between 2023 and 2025, it stated, including its dividend coverage to distribute 50% to 60% of the web earnings would stay unchanged.

“With fiscal yr 2022 we began the subsequent chapter of technique 2025,” Chief Government Bernd Montag instructed the corporate’s Capital Markets Day.

Healthineers will focus extra on preventing most cancers, cardiovascular and neurovascular ailments, leveraging its market place in imaging and robotics.

($1 = 0.8842 euros)